3F., NO. 607, Ruiguang Rd.
Neihu Dist.
Taipei City, 11492
Taiwan
TaiMed Biologics Inc. (4147.TWO) is a prominent Taiwanese biopharmaceutical company, established in 2007. With a wealth of experience in developing and manufacturing monoclonal antibodies (mAb), we have achieved a major milestone by introducing Trogarzo® (TMB-355), the first and only mAb for HIV treatment in the US and Europe, to the market.
Expedite advancement of your antibody molecules
from early stage to commercialization
TaiMed Biologics Pipeline
We are excited to share that TaiMed Biologics will be attending BioJapan 2023 in Yokohama. Our aim is to connect with innovators who are interested in licensing opportunities for our HIV therapies. Specifically, we are seeking a global marketing partner for our commercialized product, Trogarzo, which is currently the only approved mAb for HIV therapy in the US. Additionally, we are looking for a co-development and licensing partner for our clinical stage mAb combination. This product has the potential to become the world's first complete regimen for HIV therapy based on mAb. We look forward to exploring the possibilities that await us at this event!
Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
You can obtain detailed information about the use of cookies on our website by clicking on "More information”.
Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.